Lpath, Inc. (LPTN.OB) recently received a Notice of Allowance from the US Patent and Trademark Office (USPTO) on an important patent covering the use of Sphingomab™ in the treatment of cancer.
Sphingomab™ is Lpath Inc.’s monoclonal antibody against sphingosine-1-phosphate (S1P), a bioactive lipid that has been validated as a cancer drug target.
Study results demonstrating the profound anti-cancer effects of Sphingomab™ were recently published in Cancer Cell.
"Lpath's broad and deep intellectual property coverage is now supported by over 26 issued and pending patents," said Scott Pancoast, Lpath's president and chief executive officer.
"This patent, once issued, will allow Lpath to prevent the unlicensed use of Sphingomab and other S1P-binding agents in the treatment of cancer."
The murine (mouse-based) form of Sphingomab was the first antibody created utilizing Lpath Inc.’s proprietary ImmuneY2™ Technology.
Recently, Lpath, Inc. has engineered humanized versions of Sphingomab so that this potential therapeutic could be administered multiple times to cancer patients without eliciting a neutralizing immune response.
Read the full press release.
Comment Preview